KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Return on Capital Employed for 14 consecutive years, with 0.08% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed rose 15.0% year-over-year to 0.08%, compared with a TTM value of 0.08% through Sep 2025, up 15.0%, and an annual FY2024 reading of 0.06%, up 4.0% over the prior year.
  • Return on Capital Employed was 0.08% for Q3 2025 at Alnylam Pharmaceuticals, up from 0.06% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.08% in Q3 2025 and bottomed at 0.32% in Q2 2023.
  • Average Return on Capital Employed over 5 years is 0.16%, with a median of 0.23% recorded in 2022.
  • The sharpest move saw Return on Capital Employed surged 35bps in 2024, then fell -9bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.25% in 2021, then fell by -14bps to 0.28% in 2022, then soared by 65bps to 0.1% in 2023, then skyrocketed by 41bps to 0.06% in 2024, then soared by 244bps to 0.08% in 2025.
  • Business Quant data shows Return on Capital Employed for ALNY at 0.08% in Q3 2025, 0.06% in Q2 2025, and 0.04% in Q1 2025.